Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMC-IH1
- Development stage
- Unknown
- Lead developer
- De Motu Cordis
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
DMC-IH1 is an inhaled epinephrine drug-device combination product being developed by De Motu Cordis for the emergency treatment of anaphylaxis. It utilizes a proprietary dry powder inhaler (DPI) platform to deliver epinephrine directly to the lungs, providing a needle-free alternative to traditional intramuscular autoinjectors. In Phase 1 clinical studies, DMC-IH1 demonstrated rapid absorption, with plasma epinephrine concentrations reaching peak levels significantly faster than traditional autoinjectors. The product is being developed via the FDA's 505(b)(2) regulatory pathway and aims to provide a more accessible and rapid-acting treatment for severe allergic reactions.
- Other names
- Inhaled epinephrineInhaled adrenaline
02
Targets
ADRA1A (α1A)ADRA2A (α2A)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on DMC-IH1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMC-IH1.